Doxazosin Mesylate
Doxazosin mesylate, a quinazoline compound sold by Pfizer under the brand names Cardura and Carduran, is an α1-selective alpha blocker used to treat high blood pressure and urinary retention associated with benign prostatic hyperplasia (BPH).
Starting at
Product Description
| (RS)-2-[4-(2,3-Dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine |
| Trade names | Cardura |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a693045 |
| Legal status | ℞ (Prescription only) |
| Routes of administration |
oral |
| Bioavailability | 65% |
| Protein binding | 98% |
| Metabolism | Hepatic |
| Biological half-life | 22 hours |
| CAS Number | 74191-85-8 |
| ATC code | C02CA04 |
| PubChem | CID: 3157 |
| IUPHAR/BPS | 7170 |
| DrugBank | DB00590 |
| ChemSpider | 3045 |
| UNII | NW1291F1W8 |
| KEGG | D07874 |
| ChEBI | CHEBI:4708 |
| ChEMBL | CHEMBL707 |
| Formula | C23H25N5O5 |
| Molecular mass | 451.475 g/mol |
| SMILES[show] | |
| InChI[show] | |
